Acute Rejection/Infection in Heart Transplantations

心脏移植中的急性排斥/感染

• 批准号: 6993960
• 负责人: Michael A Solomon
• 金额: --
• 依托单位: CLINICAL CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6993960
• 关键词: Escherichia coli infections; animal genetic material tag; cyclosporines; diagnosis design /evaluation; diagnostic tests; disease /disorder model; gene expression; gene expression profiling; heart transplantation; immunogenetics; immunoregulation; inflammation; laboratory rat; microarray technology; postoperative complications; transplant rejection; transplantation immunology

Acute cardiac allograft rejection and infection remain significant sources of morbidity and mortality after heart transplantation, accounting for nearly 50% of reported deaths. It is often difficult to clinically distinguish between rejection and infection because they are both inflammatory processes with similar, nonspecific symptoms. However, this differential is essential for determining therapy. Identifying laboratory methods that will permit safe and concise early differentiation between rejection and infection in the transplant patient will improve outcome substantially. We have established an ACUC protocol that allows us to study whether gene microarray analysis of peripheral blood mononuclear cells (PBMC) will reliably differentiate acute heart rejection from infection in the transplanted rat. The ACUC protocol also allows us to do pilot studies necessary to support the main protocol. To date, we have established the surgical techniques necessary to successfully perform and maintain the rat transplant model. We have established a dose of cyclosporin (CSA) in this model that reliably suppresses rejection during its administration, but will permit the emergence of Grade 3 rejection upon its discontinuation. We have also determined the appropriate inocula of intra-bronchial E. coli bacteria that is sufficient to cause a pneumonia and a systemic inflammatory response without being immediately lethal in transplanted rats receiving CSA. In addition, we have used gene microarry technology to study the time course of post surgical inflammatory changes in order to determine the most opportune time to harvest the transplanted hearts (i.e. when gene microarry signatures due to surgical inflammatory changes are dissapating). Currently we are enrolling animals in the main study protocol. Our main protocol combines two well-established rat models, the first is a heterotopic heart transplantation model and the second is an E. coli pulmonary infection model. All rats will undergo heart transplantation on day 0 in conjunction with daily CSA (10 mg/kg subcutaneous) to suppress rejection. After transplant, animals will be randomized at day 6 to have CSA discontinued, in order to initiate rejection, or continued, in order to further suppress rejection. After discontinuing CSA the animals will again be randomized on day 13 to receive intrabronchial E. coli inoculation or saline inoculation. Consequently, four groups will be studied: No rejection (i.e. receiving CSA) without infection, no rejection (i.e. receiving CSA) with infection, rejection (i.e. not receiving CSA) without infection, and rejection (i.e. not receiving CSA) with infection. On day 14, all animals will be sacrificed and the blood and heart removed for gene microarray analysis. Other analytic tools that may be employed include: RT-PCR, western blot, in-situ hybridization, proteomics, immunohistochemistry, and histopathology. In addition, the animals' lungs, spleen, liver, and thymus will also be procured in the primary study and preserved for potential future analysis.

急性心脏移植排斥反应和感染仍然是心脏移植后发病率和死亡率的重要来源，占报告死亡的近50%。在临床上很难区分排斥反应和感染，因为它们都是炎症过程，具有相似的非特异性症状。然而，这种差异对于确定治疗至关重要。确定实验室方法，将允许安全和简洁的移植患者的排斥反应和感染之间的早期区分将大大改善结果。我们已经建立了一个ACUC协议，使我们能够研究是否基因微阵列分析外周血单核细胞（PBMC）将可靠地区分急性心脏排斥反应的感染移植大鼠。ACUC协议还允许我们进行必要的试点研究，以支持主要协议。迄今为止，我们已经建立了成功进行和维持大鼠移植模型所需的外科技术。我们已经在该模型中建立了环孢菌素（CSA）的剂量，该剂量在给药期间可靠地抑制排斥反应，但在停药后将允许出现3级排斥反应。并确定了支气管内E.大肠杆菌细菌，足以引起肺炎和全身炎症反应，而不会立即致命的移植大鼠接受CSA。此外，我们使用基因微阵列技术来研究术后炎症变化的时间过程，以确定收获移植心脏的最佳时间（即，当由于手术炎症变化导致的基因微阵列特征消失时）。目前，我们正在主要研究方案中招募动物。我们的主要方案结合了两种成熟的大鼠模型，第一种是异位心脏移植模型，第二种是E。coli肺部感染模型。所有大鼠将在第0天接受心脏移植，同时每日给予CSA（10 mg/kg皮下注射）以抑制排斥反应。移植后，将在第6天将动物随机分组，停用CSA以引发排斥，或继续CSA以进一步抑制排斥。停止CSA后，动物将在第13天再次随机接受支气管内E。大肠杆菌接种或生理盐水接种。因此，将研究四组：无排斥（即接受CSA）而无感染、无排斥（即接受CSA）而有感染、排斥（即不接受CSA）而无感染和排斥（即不接受CSA）而有感染。在第14天，处死所有动物，取出血液和心脏用于基因微阵列分析。可采用的其他分析工具包括：RT-PCR、蛋白质印迹、原位杂交、蛋白质组学、免疫组织化学和组织病理学。此外，还将在初步研究中采集动物的肺、脾、肝和胸腺，并保存以备将来分析。